Results of murine bone marrow transplants using mice deficient in GM-CSF and IL-3
| Oncogene . | Donor . | Recipient . | Mice (n) . | Median survival (wk) . |
|---|---|---|---|---|
| TEL/PDGFR | KO | Wild type | 4 | 2.7 |
| TEL/PDGFR | KO | KO | 8 | 3.3 |
| TEL/JAK2 | KO | Wild type | 8 | 4.7 |
| TEL/JAK2 | KO | KO | 4 | 5.3 |
| TEL/TRKC | KO | Wild type | 4 | 1.8 |
| TEL/TRKC | KO | KO | 8 | 6.8* |
| Oncogene . | Donor . | Recipient . | Mice (n) . | Median survival (wk) . |
|---|---|---|---|---|
| TEL/PDGFR | KO | Wild type | 4 | 2.7 |
| TEL/PDGFR | KO | KO | 8 | 3.3 |
| TEL/JAK2 | KO | Wild type | 8 | 4.7 |
| TEL/JAK2 | KO | KO | 4 | 5.3 |
| TEL/TRKC | KO | Wild type | 4 | 1.8 |
| TEL/TRKC | KO | KO | 8 | 6.8* |
GM-CSF indicates granulocyte-macrophage colony-stimulating factor; IL-3, interleukin 3; KO, Gmcsf−/− and Il3−/− doubly deficient mice.
Statistically significant (P < .003) difference between survival of mice transplanted into doubly deficient versus wild-type recipients.